American Pharmacists Association Foundation Joins The Bristol-Myers Squibb Foundation's $100 Million National Diabetes Initiative

Main Category: Diabetes
Article Date: 15 Nov 2010 - 5:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email to a friend ? printer friendly ? opinions ?

The American Pharmacists Association (APhA) Foundation announced it has been selected as an initial grantee in and will play a major role in the new Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge. The $100 million initiative, funded by the Bristol-Meyers Squibb Foundation, is the largest, corporate philanthropic commitment to date to fight diabetes in the United States.

The APhA Foundation - chosen as one of four initial partners - will adapt and expand the evidence-based care model successfully utilized in three innovative diabetes initiatives - The Asheville Project®, the Patient Self-Management Program for Diabetes, and the Diabetes Ten City Challenge - to 25 communities heavily affected by diabetes.

The APhA Foundation's new effort, Project IMPACT: Diabetes, IMProving America's Communities Together, will fully integrate pharmacists into the health care team in an effort to address some of the challenges faced by participants living with diabetes. Letters of support have already been received from a preliminary group of partner organizations including the American Pharmacists Association, the Center for Health Value Innovation, Giant Food Stores, HHS Office of Women's Health, the National Diabetes Education Program, U.S. Health Resource Services Administration Pharmacy Services Support Center and Walgreens.

"Diabetes is a growing problem in the United States, commented Benjamin M. Bluml, the APhA Foundation's Vice President for Research. "It is estimated that there are 23.6 million people living with diabetes in the U.S. and another 57 million with pre-diabetes. To make matters worse, only 17.9 million people are actually diagnosed with diabetes, and of those 3 million people are not being treated and another 9 million people are not being treated successfully.

Bluml continued, "Pharmacists are one of the most accessible health care providers available to the patient, and their collaborative care efforts with patients, physicians, and other health care providers have consistently helped people with diabetes improve therapeutic outcomes, increase activity, and lead healthier lives. Project IMPACT: Diabetes presents a unique opportunity to connect more patients to an inter-disciplinary health care team with a whole person orientation within the context of their community. Working with the 'Together on Diabetes' initiative and our national partners, we look forward to creating a meaningful framework for getting more evidence-based diabetes care to the people who need it the most!"

Source:
Bristol-Myers Squibb Foundation
American Pharmacists Association Foundation

Please rate this article:
(Hover over the stars
then click to rate)

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

View the original article here

Press Release - Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis

Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis - Diabetes Health My Account ??|??Subscribe??|??Contact Us??|??Donate Search Home Charts Recipes Digital Edition TV Apps Community Kids & Teens Type 2 Issues Type 1 Issues Professional Issues Pre-Diabetes Beginners International Health Events History Camps for Kids Online Resources Dating World Diabetes Day Pets All Sections Products Product Directory Charts Syringes Insulin Pumps Meters Pens Software CGMs Books Medical ID Jewelry Lancing Devices Infusion Sets Carrying Cases Pen Needles All Sections Complications & Care Heart Care & Heart Disease Low Blood Sugar Foot Care Kidney Care (Nephropathy) Nerve Care (Neuropathy) Eye Care (Retinopathy) Hypoglycemia Unawareness Sexual Issues Geriatrics Depression Insulin Resistance Skin Care Lipid Problems Wound Care Reversing Complications All Sections Food Recipes Diets Vitamins Food News Nutrition Advice Low Carb Supplements Glycemic Index & Carb Counting Beverages Low Calorie & Low Fat Sugar & Sweeteners Desserts Herbs Dinner Lunch All Sections Columns Cartoons & eCards Personal Stories Letters to the Editor Inspiration My Own Injection Book Reviews Motivation Heroes Making a Difference CDE of the Month Doctors & Nurses Love and Diabetes After All These Years All Sections Medications Insulin Type 2 Medications Metformin Pharmacy Lantus Byetta Actos Animal Insulin Januvia Victoza Symlin Apidra Onglyza Voglibose All Sections Research Nutrition Research Islet & Pancreas Transplant Medications Research Health Research The Cure Beta Cells Other Lab Tests Artificial Pancreas New Cure Research Case Studies All Sections Fitness Exercise Weight Loss Bariatric Surgery Success Stories Amphetamines All Sections Psychology Adolescent Boys Adolescent Girls Living with Diabetes Support Groups Women's Issues Men's Issues Teenagers Insulin Omission All Sections Monitoring Blood Sugar A1c Test Noninvasive Monitors Urine Test Laboratory Tests All Sections Health Care Health Insurance Hospital Care Endocrinology Complementary Therapies Smoking CDE Physical Therapy All Sections Legal Government & Policy Discrimination Drivers License & Pilot License Politics Driving 504 Plan in School Lobbying All Sections Pregnancy Childbirth Breastfeeding Gestational Diabetes All Sections Celebrities Nick Jonas Jay Hewitt Scott Dunton Elliott Yamin All Sections About UsAbout UsPublisher's LetterAdvertisingContact UsPress RoomSubmission GuidelinesPrivacy Policy Help function fbs_click() {u=location.href;t=document.title;window.open('http://www.facebook.com/sharer.php?u='+encodeURIComponent(u)+'&t='+encodeURIComponent(t),'sharer','toolbar=0,status=0,width=626,height=436');return false;}

See What's Inside… Living His Dream of Law Enforcement: Lt. Jose Lopez Diabetes & Alcohol Diabetes and Autoimmunity Insulindependence Precious Pooch

View Diabetes Health Magazine For Free Online

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To ViewFree Subscription to Diabetes Health Professional

If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.

Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.

Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.

Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.

Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.

As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!

Email Address: Area of Interest: Consumer Professional How To Change Your Newsletter Email…

You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive

Then enter your new email address in the above form and click "Subscribe"

LatestPopularTop RatedLatest Community Articles

Diabetes Association of Atlanta Caps Off Successful Diabetes UniversityHandle online advice with careBristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes CrisisBe Part of the CureThis World Diabetes Day, Measure Your Risk of Type 2 DiabetesDiabetes Month: Get Involved!Solianis Working on Noninvasive Continuous Glucose Monitoring for Patients With DiabetesBring Diabetes To Light! JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing Is Correcting Low Blood Sugars Caused by Exercise Making You Fat?Popular Community Articles

Type 1 Pop Star, Nick Jonas Tells His StoryLantus and Levemir: What's the Difference?Bret Michaels, Diabetic Lead Singer of PoisonThe History of DiabetesLegal and Illegal Drugs: What Every Person With Diabetes Should Know Before They PartyCinnamon: Should It Be Taken as a Diabetes Medication?Why Eating Too Many Carbs Makes You FatLow Carbohydrate Diets: Why You Don't Want the "Experts" to Tell You What to EatScrawny Boy With Type 1 Diabetes Becomes Mr. UniverseInsulin For Type 2 Diabetes: Who, When, And Why?Highly Recommended Community Articles

Type 1 Pop Star, Nick Jonas Tells His StoryJonas Brothers Band Member Reveals He Has Diabetes: Nick Jonas, age 14, hopes his story will inspire other kids with diabetesJonas Brothers Update: Diabetes Has Not Slowed Down 15-Year-Old Nick JonasWoman Loses 134 Pounds in One YearLow Carbohydrate Diets: Why You Don't Want the "Experts" to Tell You What to EatBret Michaels, Diabetic Lead Singer of PoisonInsulin For Type 2 Diabetes: Who, When, And Why?Has Anyone Else Reversed Diabetes Complications? If You Have, I Want to Hear From You!Mr. Universe Assaulted by Police During Low Blood Sugar EpisodeScrawny Boy With Type 1 Diabetes Becomes Mr. UniverseCommunity ArchivesBrowse the Community ArchivesSubscribe to the Community RSS Feed Print|Email|Share|Comments (1)Email to a Friend

Send a link to this page to your friends and colleagues.

Your Name:Your Email:Recipient's Name:Recipient's Email:CloseBristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes CrisisNov 15, 2010 This press release is an announcement submitted by Bristol-Myers Squibb Foundation , and was not written by Diabetes Health.

The?Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge,?a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.

The largest corporate philanthropic commitment to fighting type 2 diabetes in the United States,?Together on Diabetes®?will draw upon the Foundation's deep experience supporting community-based, non-medical support services that complement medical care and improve health outcomes. This approach - first employed by the Foundation in 1999 as part of its groundbreaking $150 million?SECURE THE FUTURE®?initiative to fight HIV/AIDS in Africa - helps remove barriers to diagnosis and care while empowering patients to understand their role in managing their disease and reducing the risks it can pose to their health.

Together on Diabetes®?is the Foundation's first large-scale diabetes initiative. Working with a wide variety of community-based, regional and national partners,?Together on Diabetes®?will support efforts to develop and expand effective patient self-management programs and broadly engage affected communities in the fight against type 2 diabetes. The initiative's "innovation fund" will encourage and test new ideas for controlling type 2 diabetes, which today affects about one in 12 Americans and could affect as many as one in three Americans by 2050.?Together on Diabetes®?also released its first request for proposals, which focuses on African American women.

"Type 2 diabetes is one of the United States' greatest health challenges and disproportionately affects the poor, minorities and the elderly, many of whom are not receiving the care and support they need to improve their glycemic control," says Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "Together on Diabetes®?will draw on the strengths of communities and support public- and private-sector partners coming together to identify and implement disease management approaches that work for large segments of the population."

The U.S. Centers for Disease Control and Prevention (CDC) reports that 57 million Americans are pre-diabetic and at increased risk of developing type 2 diabetes in the next 10 years. About 1.6 million new cases of diabetes are diagnosed in people age 20 and older each year. African Americans, Hispanics, Native Americans and Asian Americans, including Native Hawaiians and other Pacific Islanders, and the elderly, are more likely to develop type 2 diabetes than non-Hispanic whites.

"This initiative harnesses the strength of corporate philanthropy and non-profit sector expertise to enhance type 2 diabetes awareness in the most at risk and affected communities," said Deborah Fillman, M.S., R.D., L.D., C.D.E., president of the American Association of Diabetes Educators. "We believe it will yield clear and measurable results and reduce the scope of the type 2 diabetes epidemic in the U.S."

The human and economic costs of uncontrolled diabetes are staggering and the need to step up control efforts is urgent. Nearly half of all patients diagnosed with type 2 diabetes - 48.3 percent - do not have their disease adequately controlled through a combination of diet, physical activity and medication. Patients with uncontrolled type 2 diabetes face increased risk of complications such as cardiovascular disease, high blood pressure and stroke; damage to the nerves, eyes and kidneys; and amputation of the fingers, toes or limbs. CDC estimates the U.S. spent $116 billion in 2007 for direct medical services to treat diagnosed cases of diabetes and $58 billion in indirect costs such as disability and lost work time.

"The health implications of type 2 diabetes are significant, both for the individual and for society," says John Damonti, president, Bristol-Myers Squibb Foundation, and vice president, Corporate Philanthropy, Bristol-Myers Squibb. "Our experiences with SECURE THE FUTURE®?and other Foundation initiatives around the world have shown that mobilizing affected communities can have a profound impact on improving patient quality of life and health outcomes."

The Foundation will make grants and forge partnerships through two processes: ongoing, opportunistic grantmaking and themed requests for proposals, which will be issued each November during National Diabetes Month. The initial grantees for Together on Diabetes®?are:

The American Academy of Family Physicians Foundation, in partnership with Peers for Progress, National Council of La Raza and the University of North Carolina's Gillings School of Global Public Health, will incorporate patient self-management education, peer support and community outreach for low-income Hispanics and African Americans into the patient-centered medical home model.The American Association of Diabetes Educators will conduct a pilot study of the effectiveness and sustainability of a flexible, multi-level diabetes education and support team that serves minority populations and that utilizes professional and lay health workers.The American Pharmacists Association Foundation, working with government agencies, professional associations, pharmacy chains and others, will adapt and expand the evidence-based Asheville Project model to patients covered by public and private health insurance in 25 communities heavily affected by diabetes. In this model, patients receive diabetes education and then are teamed with community-based pharmacists who make sure they use their medications correctly.The United Hospital Fund, working with the New York City Department of Health and Mental Hygiene and the Department for the Aging, will develop and test an integrated, community-based diabetes control strategy for seniors living in "naturally occurring retirement communities" and the surrounding neighborhoods.

Foundation seeks additional proposals

Together on Diabetes®?first request for proposals focuses on African American women. Five grants up to $300,000 each will be awarded. African American women represent one of the highest risk groups for type 2 diabetes based on prevalence and disease burden. About one in 10 African American women age 20 and older has diabetes, a rate that more than doubles to one in four for African American women over 55. African Americans also suffer high rates of diabetes' most serious complications: blindness, amputation and kidney failure. The purpose of the request for proposals is to encourage, identify and promote new evidence-based approaches to empowering African American women to control their diabetes while taking into account the opportunity they have to influence the health of their families and communities as well.

You can learn more about?Together on Diabetes®?at?TogetherOnDiabetes.com.

About the Bristol-Myers Squibb Foundation

The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

?

Categories: Community, Pre-Diabetes, Type 2 Issues

Facebook MySpace Digg Recommend this :Not at allSomewhatModeratelyHighlyVery Highly
Average Rating:

You May Also Be Interested In...Click Here To View Or Post Comments 1 comment - Nov 15, 2010-

Home | Charts | Forums | Digital Edition | TV | Subscribe | Contact Us | Donate | Sitemapⓒ1991-2010 Diabetes Health

View the original article here

Juvenile Diabetes Research Foundation And Amylin Pharmaceuticals Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose

Main Category: Diabetes
Also Included In: Clinical Trials / Drug Trials;??Pharma Industry / Biotech Industry
Article Date: 17 Nov 2010 - 7:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email to a friend ? printer friendly ? opinions ?

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

Prior studies at UT Southwestern conducted in animal models with type 1 diabetes showed an improvement in blood glucose, blood fats, and cholesterol following administration of the hormone. The clinical study will help to determine if similar improvements in glucose, and reduction of the amount of insulin required, can be achieved in people with type 1 diabetes. Leptin is a hormone secreted by fat cells that plays a fundamental role in the regulation of glucose metabolism.

"Better blood glucose control means healthier living for people with type 1 diabetes," said Aaron Kowalski, Ph.D., Assistant Vice President of Treatment Therapies at JDRF. "If effective in humans, metreleptin, when used with insulin, could change the way people manage their disease. Less insulin usage and fewer low blood sugar episodes would represent a significant improvement in quality of life for certain people living with type 1 diabetes today."

"Building on our development experience with type 1 diabetes, we continually look for ways to unleash the potential of peptide and protein science to help the millions of patients with diabetes better manage their disease," said David Maggs, MD, MRCP, Vice President for R&D Strategic Relations at Amylin. "We are pleased to partner on this important research program with an organization that shares our passion for investigating the potential promise of new and innovative therapies."

The research collaboration agreement between JDRF and Amylin is part of JDRF's Industry Discovery and Development Partnership (IDDP) program through which JDRF partners with pharmaceutical, biotechnology, and medical device companies focused on the discovery, development, and delivery of therapeutics and devices for type 1 diabetes and its complications. Since the IDDP program was established in 2004, JDRF has funded 35 partnerships with 29 companies and committed approximately $71 million to accelerate research that will lead to better treatments and a cure for type 1 diabetes.

About the Study

This proof-of-concept clinical study will investigate whether treatment with metreleptin can help improve blood sugar control and decrease the daily doses of insulin required in patients with type 1 diabetes. This is the first clinical study evaluating metreleptin treatment in patients with type 1 diabetes. The study will also evaluate whether treatment with metreleptin can improve variability in blood sugar levels, including the propensity for hypoglycemia (low blood sugar levels), which affects many people with type 1 diabetes.

Conducted by researchers at UT Southwestern in Dallas, Texas, including Roger Unger, MD, professor of internal medicine, the study will enroll 12 to 15 patients with type 1 diabetes. Patients will add metreleptin twice a day to their usual insulin therapy over a five-month period. The insulin dosage will gradually be reduced to further characterize the effect of metreleptin on overall blood glucose. This study will build on recent preclinical findings by Dr. Unger and his team that showed leptin administration improved blood glucose levels, blood fats, and cholesterol in animal models of type 1 diabetes.

"We were highly encouraged by the results of our study of leptin in animal models and look forward to learning whether using metreleptin with insulin yields similar results in humans," said Dr. Unger. "Achieving a substantial reduction in insulin doses and lowering the risk of low blood glucose levels could enhance the quality of life for people with type 1 diabetes."

About Leptin

Leptin, a fat cell hormone that plays a key role in regulating metabolism, was first discovered in 1994 by Dr. Jeffrey Friedman of The Rockefeller University in New York. Dr. Friedman has won numerous awards during his career and recently won the 2010 Lasker Award in basic medical research for his work. Metreleptin, an analog of human leptin, has been studied as a potential treatment for obesity, type 2 diabetes, and severe lipodystrophy.

Source: Juvenile Diabetes Research Foundation

Please rate this article:
(Hover over the stars
then click to rate)

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

View the original article here